Leon Hooftman, an experienced clinician and drug developer, has become chief medical officer at ISA Pharmaceuticals BV which is developing immunotherapies against cancer and viral infections.
Dr Hooftman joins ISA from Allecra Therapeutics Ltd where he served as CMO. He has also headed clinical development at Celltech Group Plc (now UCB) and was director of clinical science, oncology and immunology at Roche where he led the team that successfully completed a registration study for rituximab for non-Hodgkin lymphoma.
ISA Pharmaceuticals announced the appointment on 30 April 2018.
Copyright 2018 Evernow Publishing Ltd.